Clinical trials: Histiocytic Disorders
Histiocytic Disorders
Single-agent Cobimetinib for Adults With Histiocytic Disorders
The purpose of this study is to find out what effects, good or bad, Cobimetinib has in patients with histiocytosis. Cobimetinib is an investigational oral medication that blocks MEK1.
- Trial name
- NCT02649972
- Testing
- Cobimetinib
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center